Cargando…

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need further research. In this study, we aimed to invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jize, Ma, Xiaomin, Liu, Chuxuan, Cheng, Yang, Li, Bingjun, Zhang, Wenjie, Zeng, Runzhi, Chen, Qishuai, Zhang, Yun, Hu, Sanyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944415/ https://www.ncbi.nlm.nih.gov/pubmed/36843945 http://dx.doi.org/10.3389/fphar.2023.1136614

Ejemplares similares

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
por: Zheng, Cankun, et al.
Publicado: (2022)

The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy
por: Chaudhri, Apoorvi, et al.
Publicado: (2023)

Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis
por: Ding, Huanxin, et al.
Publicado: (2022)

Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
por: Limatola, Cristina, et al.
Publicado: (2014)

The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
por: Pawelec, Paulina, et al.
Publicado: (2020)

Involvement of CX3CL1/CX3CR1 Signaling in Spinal Long Term Potentiation
por: Bian, Chao, et al.
Publicado: (2015)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Hydrogen Sulfide Inhibits the Development of Atherosclerosis with Suppressing CX3CR1 and CX3CL1 Expression
por: Zhang, Huili, et al.
Publicado: (2012)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
por: Zhao, Yating, et al.
Publicado: (2021)

Fractalkine/CX3CL1 in Neoplastic Processes
por: Korbecki, Jan, et al.
Publicado: (2020)

CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection
por: Chen, Peiqing, et al.
Publicado: (2016)

Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2019)

Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice
por: Winter, Aimee N., et al.
Publicado: (2020)

Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease
por: von Vietinghoff, Sibylle, et al.
Publicado: (2021)

Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation: Targeting CX3CL1 to treat heart diseases
por: Zou, Lin, et al.
Publicado: (2023)

Cochlear resident macrophage mediates development of ribbon synapses via CX3CR1/CX3CL1 axis
por: Song, Xinyu, et al.
Publicado: (2022)

Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease
por: Hu, Yonghui, et al.
Publicado: (2022)

CX3CL1 intracellular domain and adult neurogenesis
por: Benoit, Marc R., et al.
Publicado: (2019)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Repopulating retinal microglia restore endogenous organization and function under CX3CL1-CX3CR1 regulation
por: Zhang, Yikui, et al.
Publicado: (2018)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
por: Wei, Yuhua, et al.
Publicado: (2022)

CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
por: Zhuang, Quan, et al.
Publicado: (2017)

CX3CL1–CX3CR1 Axis: A New Player in Coeliac Disease Pathogenesis
por: Fernández-Prieto, Marta, et al.
Publicado: (2019)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy
por: Chamcheu, Jean Christopher, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1‐CX3CR1 dependent manner and induce tumour cell apoptosis
por: Miao, Shuo, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

The Chemokine CX3CL1 (Fractalkine) and its Receptor CX3CR1: Occurrence and Potential Role in Osteoarthritis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2014)

Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
por: Sato, Michihito, et al.
Publicado: (2011)

Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
por: Imai, Toshio, et al.
Publicado: (2016)

Microglia and Aging: The Role of the TREM2–DAP12 and CX3CL1-CX3CR1 Axes
por: Mecca, Carmen, et al.
Publicado: (2018)

Prevention of lipopolysaccharide-induced preterm labor by the lack of CX3CL1-CX3CR1 interaction in mice
por: Mizoguchi, Mika, et al.
Publicado: (2018)

Fractalkine Signalling (CX(3)CL1/CX(3)CR1 Axis) as an Emerging Target in Coronary Artery Disease
por: Loh, Shu Xian, et al.
Publicado: (2023)

Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model
por: Zhang, Jingjing, et al.
Publicado: (2018)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qdk7iggv1kcoe28iu1ee1152ef